Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies.

Spilker ME, Chen X, Visswanathan R, Vage C, Yamazaki S, Li G, Lucas J, Bradshaw-Pierce EL, Vicini P.

Clin Cancer Res. 2017 Feb 15;23(4):1080-1090. doi: 10.1158/1078-0432.CCR-16-1164. Epub 2016 Aug 22.


Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo.

Kong J, Chuddy J, Stock IA, Loria PM, Straub SV, Vage C, Cameron KO, Bhattacharya SK, Lapham K, McClure KF, Zhang Y, Jackson VM.

Br J Pharmacol. 2016 May;173(9):1452-64. doi: 10.1111/bph.13439. Epub 2016 Mar 17.


Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.

Giragossian C, Vage C, Li J, Pelletier K, Piché-Nicholas N, Rajadhyaksha M, Liras J, Logan A, Calle RA, Weng Y.

Drug Metab Dispos. 2015 Jun;43(6):803-11. doi: 10.1124/dmd.114.061713. Epub 2015 Mar 24.


Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.

Weng Y, Chabot JR, Bernardo B, Yan Q, Zhu Y, Brenner MB, Vage C, Logan A, Calle R, Talukdar S.

PLoS One. 2015 Mar 19;10(3):e0119104. doi: 10.1371/journal.pone.0119104. eCollection 2015.


Study of CRTC2 pharmacology using antisense oligonuceotides.

Dullea R, Salatto C, Sciabola S, Chen T, Dimattia D, Gandhok H, Kreeger J, Weng Y, Clark T, Vage C, Stanton R.

Nucleic Acid Ther. 2014 Apr;24(2):127-38. doi: 10.1089/nat.2013.0456. Epub 2013 Dec 31.


Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.

Liu KK, Cornelius P, Patterson TA, Zeng Y, Santucci S, Tomlinson E, Gibbons C, Maurer TS, Marala R, Brown J, Kong JX, Lee E, Werner W, Wenzel Z, Vage C.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. doi: 10.1016/j.bmcl.2009.10.112. Epub 2009 Oct 30.


Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation.

Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, Coffing SL, Cheung JR, Vage C, Lame ME, Chiang P, McClure KF, Maurer TS, Coelho RV Jr, Soliman VF, Schildknegt K.

Drug Metab Dispos. 2007 Jun;35(6):848-58. Epub 2007 Mar 7.


Supplemental Content

Support Center